9:00 a.m.

Keynote Address—Infectious Diseases of the 21st Century: A New World Order, Michael T. Osterholm, PhD, MPH, University of Minnesota Health

The emergence and re-emergence of infectious diseases involves many interrelated factors. As the 21st century begins, already new agents have been identified, and new outbreaks have occurred. Solutions to limiting the spread of emerging infectious diseases will require cooperative efforts among many disciplines and entities worldwide. The international public health and medical communities and global political leadership need to reconsider their approach to the prevention, control and treatment of these emerging infections. Our keynote speaker today will define these diseases and major factors contributing to the current emergence of infectious diseases of critical global importance. This presentation will also provide the implications of modern infectious diseases for your community, workplace and family.

Learning Objectives:

1. Describe the major factors contributing to the current emergence of infectious diseases of critical global importance.
2. Discuss the common features of pandemic potential for infectious diseases such as H5N1 and H7N9 influenza viruses, Middle East Respiratory Syndrome virus (MERS) and West Africa Ebola virus.
3. Describe how the international public health and medical communities and global political leadership need to reconsider their approach to the prevention, control, and treatment of emerging infections.
4. Understand the implications of modern infectious diseases for your community, workplace and family.

10:30 a.m.

The Use of New Agents and Their Roles in the Management, Control, and Prevention of Type 2 Diabetes, Richard Bergenstal, MD, International Diabetes Center

Pharmacologic therapy of type 2 diabetes has changed dramatically in the last 10 years, with new drugs and drug classes becoming available. These drugs allow for the use of combination oral therapy, often with improvement in glycemic control that was previously beyond the reach of medical therapy. Early initiation of pharmacologic therapy is associated with improved glycemic control and reduced long-term complications in type 2 diabetes. This session will outline the use of new agents available for patient diabetes and the roles these new agents play in the management of type 2 diabetes.

Learning Objectives:

1. List drug classes used for the treatment of type 2 diabetes.
2. Discuss the treatment of type 2 diabetes with combinations of drugs and insulin.
3. Review the American Diabetes Association (ADA) guidelines for pharmacologic therapy for type 2 diabetes.

11:15 a.m.

Congestive Heart Failure: Updates in Management, Joseph G. Rogers, MD, Duke University Medical Center

Congestive heart failure (CHF) affects almost 5 million people in the United States, according to the American Heart Association (AHA). Utilizing opportunities to improve the delivery of comprehensive heart-failure care and implementing strategies to improve patient outcomes are imperative in the management of this condition, which is currently associated with a five-year mortality rate of 50 percent and the highest 30-day readmission rate in the United States at 26 percent. This presentation will provide an overview of the rationale for new guidelines and discuss key elements of evidence-based management for heart failure.

Learning Objectives:

1. Identify key elements of evidence-based management for heart failure.
2. Provide an overview of the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) jointly produced heart-failure-treatment guidelines for each stage of heart failure.
3. Describe the current research that is likely to define the future of heart-failure management.

1:00 p.m.

Lung Transplant: Current Status, What’s New? Michael Petty, PhD, RN, CCNS, ACNS-BC, University of Minnesota Health

Lung transplantation is an accepted modality of treatment for advanced-stage lung disease. Lung transplantation for advanced-stage lung disease is a complex therapy with significant risk of perioperative morbidity and mortality, therefore, each patient needs to be evaluated individually and meet a broad range of physical and psychosocial criteria to become eligible for transplantation. This session will discuss the complexity of lung transplantation, management strategies and the guidelines for recipient selection.

Learning Objectives:

1. List the advanced-stage pulmonary diseases that are indications for lung transplantation.
2. State the appropriate timing for referral to a transplant program and describe the patient-selection process.
3. Discuss management strategies for patients before, during and after their transplant surgery.

2:00 p.m.

Who Is Likely to Receive a Kidney Transplant? Anton I. Skaro, MD, PhD, FRCS(C), FACS, Northwestern Memorial Hospital

A kidney transplant is often the best treatment for kidney failure. Despite a steady increase in the number of transplants involving living kidney donors performed each year in the United States, there still remains a significant shortage of kidneys available for transplant. When a living compatible donor is not available, the patient’s name may be placed on the kidney transplant waiting list to receive a kidney. The wait time for a kidney may take years since, on average, every 14 minutes a new name is placed on a kidney wait list. This session will discuss the kidney transplant allocation algorithm and how to best manage patients waiting for a kidney transplant.

Learning Objectives:

1. Review the kidney transplantation allocation algorithm.
2. Discuss management strategies for patients that are listed and likely to receive a kidney transplant.
3. List reasons why patients are not likely to receive a kidney transplant.

3:15 p.m.

Multiple Myeloma Treatment Options: Does One Size Fit All? Francis K. Buadi, MD, Mayo Clinic

There has been tremendous progress made in the treatment of multiple myeloma in the last decade, resulting in improved overall survival for patients, including those with high-risk disease and those ineligible for transplantation. This session will discuss the role of autologous stem cell transplantation for multiple myeloma and treatment options for nontransplant candidates, as well as treatment options for the relapsed patient.

Learning Objectives:

1. State the role of autologous SCT for MM.
2. Review treatment options for patients with relapsed disease.
3. Discuss the treatment options for nontransplantation candidates.

4:15 p.m.

Pediatric Palliative Care: Navigating Towards Comfort, Richard D. Goldstein, MD, Boston Children's Hospital

Palliative care focuses on the prevention and relief of suffering for patients with serious, chronic, and life-threatening illnesses. The aim of palliative care is to achieve the best possible quality of life for patients and their families. Despite great advances in controlling pain, health care professionals struggle to provide high quality pain management when caring for pediatric patients. This presentation will provide a comprehensive overview of the physical, psychosocial, and spiritual needs of children and their families.

Learning Objectives:

1. Identify the challenges faced by health care professionals when managing a child’s pain.
2. Review the medical criteria for a pediatric palliative care program.
3. Recognize the impact of an effective pain- and symptom-management program to help children achieve the best possible quality of life.